Genfit (GNFT) Competitors $4.31 +0.05 (+1.17%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends GNFT vs. ETNB, TYRA, RAPP, RLAY, ERAS, AUTL, EOLS, PLRX, CRON, and CGEMShould you be buying Genfit stock or one of its competitors? The main competitors of Genfit include 89bio (ETNB), Tyra Biosciences (TYRA), Rapport Therapeutics (RAPP), Relay Therapeutics (RLAY), Erasca (ERAS), Autolus Therapeutics (AUTL), Evolus (EOLS), Pliant Therapeutics (PLRX), Cronos Group (CRON), and Cullinan Therapeutics (CGEM). These companies are all part of the "pharmaceutical products" industry. Genfit vs. 89bio Tyra Biosciences Rapport Therapeutics Relay Therapeutics Erasca Autolus Therapeutics Evolus Pliant Therapeutics Cronos Group Cullinan Therapeutics Genfit (NASDAQ:GNFT) and 89bio (NASDAQ:ETNB) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, community ranking, risk and dividends. Do analysts rate GNFT or ETNB? Genfit currently has a consensus target price of $13.00, indicating a potential upside of 201.62%. 89bio has a consensus target price of $30.33, indicating a potential upside of 280.12%. Given 89bio's higher possible upside, analysts clearly believe 89bio is more favorable than Genfit.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genfit 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.0089bio 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.86 Which has more volatility and risk, GNFT or ETNB? Genfit has a beta of 1.25, indicating that its stock price is 25% more volatile than the S&P 500. Comparatively, 89bio has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500. Which has better valuation & earnings, GNFT or ETNB? Genfit has higher revenue and earnings than 89bio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGenfit$41.31M5.21-$31.27MN/AN/A89bioN/AN/A-$142.19M-$2.91-2.74 Does the MarketBeat Community favor GNFT or ETNB? 89bio received 39 more outperform votes than Genfit when rated by MarketBeat users. However, 69.39% of users gave Genfit an outperform vote while only 64.46% of users gave 89bio an outperform vote. CompanyUnderperformOutperformGenfitOutperform Votes6869.39% Underperform Votes3030.61% 89bioOutperform Votes10764.46% Underperform Votes5935.54% Is GNFT or ETNB more profitable? Genfit's return on equity of 0.00% beat 89bio's return on equity.Company Net Margins Return on Equity Return on Assets GenfitN/A N/A N/A 89bio N/A -59.58%-52.21% Do insiders & institutionals have more ownership in GNFT or ETNB? 2.2% of Genfit shares are held by institutional investors. 4.2% of Genfit shares are held by company insiders. Comparatively, 2.8% of 89bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the media favor GNFT or ETNB? In the previous week, 89bio had 7 more articles in the media than Genfit. MarketBeat recorded 10 mentions for 89bio and 3 mentions for Genfit. Genfit's average media sentiment score of 0.00 beat 89bio's score of -0.17 indicating that Genfit is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genfit 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral 89bio 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryGenfit beats 89bio on 10 of the 15 factors compared between the two stocks. Ad Crypto Swap Profits[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get Genfit News Delivered to You Automatically Sign up to receive the latest news and ratings for GNFT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GNFT vs. The Competition Export to ExcelMetricGenfitBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$212.95M$2.93B$5.07B$8.89BDividend YieldN/A1.91%4.99%4.07%P/E RatioN/A15.0083.5712.93Price / Sales5.21280.711,220.3088.33Price / CashN/A168.0739.4636.25Price / Book2.914.696.936.25Net Income-$31.27M-$41.63M$119.12M$225.93M7 Day Performance-4.65%-4.73%-1.83%-1.32%1 Month Performance-27.20%-6.53%-3.64%0.60%1 Year Performance35.11%25.63%31.64%26.23% Genfit Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNFTGenfit1.4608 of 5 stars$4.31+1.2%$13.00+201.6%+27.1%$212.95M$41.31M0.00120ETNB89bio1.4925 of 5 stars$7.98-0.1%$30.33+280.1%+3.1%$847.95MN/A0.0040TYRATyra Biosciences3.0757 of 5 stars$15.87-2.1%$31.00+95.3%+40.8%$820.27MN/A0.0020RAPPRapport Therapeutics1.8437 of 5 stars$22.19-0.4%$35.00+57.7%N/A$814.92MN/A0.00N/ANews CoverageRLAYRelay Therapeutics3.2712 of 5 stars$4.66-2.9%$21.22+355.4%-44.5%$803.44M$25.55M0.00304Gap DownHigh Trading VolumeERASErasca2.8027 of 5 stars$2.64-5.4%$6.08+130.4%+17.3%$788.81MN/A0.00126Analyst ForecastAnalyst RevisionAUTLAutolus Therapeutics3.4682 of 5 stars$2.80-5.1%$10.15+262.5%-36.5%$784.98M$1.70M0.00330Analyst UpgradeEOLSEvolus4.0221 of 5 stars$12.63+1.9%$23.00+82.1%+28.4%$784.55M$202.09M0.00170Positive NewsPLRXPliant Therapeutics3.4847 of 5 stars$12.73-0.5%$40.57+218.7%-11.4%$778.32M$1.58M0.0090CRONCronos Group1.7856 of 5 stars$2.01-1.0%$3.00+49.3%-3.8%$776.06M$87.24M-15.46356CGEMCullinan Therapeutics1.8234 of 5 stars$12.58-4.0%$31.67+151.7%+43.6%$762.78M$18.94M0.0030Analyst Revision Related Companies and Tools Related Companies 89bio Alternatives Tyra Biosciences Alternatives Rapport Therapeutics Alternatives Relay Therapeutics Alternatives Erasca Alternatives Autolus Therapeutics Alternatives Evolus Alternatives Pliant Therapeutics Alternatives Cronos Group Alternatives Cullinan Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GNFT) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genfit S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genfit With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
